Oramed Pharmaceuticals
ORMP
55 hedge funds and large institutions have $17M invested in Oramed Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 11 closing their positions.
320% more call options, than puts
Call options by funds: $21K | Put options by funds: $5K
11% more capital invested
Capital invested by funds: $15.2M → $17M (+$1.73M)
2.47% more ownership
Funds ownership: 14.6% → 17.07% (+2.5%)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 59 → 55 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.04M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$272K |
| 3 |
Millennium Management
New York
|
+$66.3K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$54.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$99.1K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$25.9K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$22.2K |
| 4 |
Two Sigma Investments
New York
|
-$21.2K |
| 5 |
JP Morgan Chase
New York
|
-$17.8K |
ORMP Hedge Fund Activity: Q3 2024 in Review
55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2024, worth a combined $17M — up 11% from $15.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ORMP and 7 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was BML Capital Management, adding an estimated $2.04M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $99.1K sold.
- 55 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2024, down from 59 in Q2 2024.
- Funds reported $17M of Oramed Pharmaceuticals stock for Q3 2024, up 11% quarter-over-quarter.
- 7 funds opened new Oramed Pharmaceuticals positions in Q3 2024 and 11 closed out, a net change of -4 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2024 was BML Capital Management, an estimated $2.04M added.
- The largest Oramed Pharmaceuticals seller in Q3 2024 was D.E. Shaw & Co, an estimated $99.1K sold.
Based on aggregated 13F filings for Q3 2024.